Clinical Trial Update: Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRISE） [Phase 4]

View source ↗

Summary

Phase 4 trial comparing upadacitinib to infliximab as second-line therapy for acute severe ulcerative colitis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Infliximab (infliximab)
• Upadacitinib (upadacitinib)

Snippet

Sponsor: Xijing Hospital of Digestive Diseases | Conditions: Acute Severe Ulcerative Colitis | Phase 4 | Status: RECRUITING